Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

✍ Scribed by Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico Montefusco; Enrica Morra; Mario Annunziata; Andrea Camera; Francesco Cavazzini; Fabio Stagno; Patrizia Pregno; Emilio Usala; Valeria Santini; Pier Paolo Piccaluga; Alessandro Isidori

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 640 KB
• Volume: 85
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.21871